New insulin pump study aims to simplify diabetes management for type 2 patients
NCT ID NCT07070830
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study tested whether a simplified approach to starting automated insulin delivery works safely in adults with type 2 diabetes. 56 participants used the Omnipod M System with a continuous glucose monitor, starting with either a lower or higher insulin dose. The goal was to see how well the system controlled blood sugar and how safe it was.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Omnipod M Automated Insulin Delivery System with Dexcom G6 continuous glucose monitor
What this could lead to
If successful, this could make it easier for people with type 2 diabetes to start using an automated insulin pump, potentially improving blood sugar control without complex setup.
What could go wrong
This was a small, early feasibility study (56 participants) with no control group. Results may not apply to all people with type 2 diabetes, and the device still requires careful monitoring.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES MELLITUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
AccellaCare
Wilmington, North Carolina, 28401, United States
-
Disease & Glandular Disease Clinic
San Antonio, Texas, 78229, United States
-
Emory University
Atlanta, Georgia, 30303, United States
-
Joslin Diabetes Center
Boston, Massachusetts, 02215, United States
-
MassResearch LLC.
Waltham, Massachusetts, 02453, United States
-
University of Colorado
Aurora, Colorado, 80045, United States